Minimal Residual Disease in Acute Myeloid Leukemia
Alexandra Gomez-Arteaga1, Monica L Guzman2
1Department of Medicine, Division of Hematology and Oncology, Weill Cornell Medicine - New York Presbyterian Hospital, New York, NY, USA.
Abstract:
Monitoring measurable (minimal) residual disease (MRD) in acute myeloid leukemia (AML) has greatly increased our ability to assess chemosensisitivity to treatment as well as the duration of treatment responses. There is strong evidence to support its prognostic value for long-term outcomes at different time points and across assays and targets. It's role as a surrogate endpoint to define risk-adapted strategies is still under evaluation. In this chapter, we will discuss the definition of MRD in AML, the potential contribution of leukemia stem cells (LSCs) to MRD and we will review all the current approaches to assess residual disease including the 2018 European Leukemia Network (ELN) working group recommendations for MRD standardization in AML. In addition, a summary of MRD studies associated to prognosis will be described.
More Related Videos
Related Concept Videos
Residual Plots
When the residual values are plotted against the variable x, it is called a residual...
Residual Stresses
Residual Stresses in Circular Shafts
Residual Stresses in Bending
Residuals and Least-Squares Property
If the observed data point lies above the line, the residual is positive, and the line underestimates the actual data value for y. If the observed data point lies below the line, the residual is negative, and the line overestimates the actual data value for y.
The process of fitting the best-fit...
Differentiation of Common Myeloid Progenitor Cells


